Amarantus Founders Gerald and Dr. John Commissiong Selected as Black Money's "50 Most Important African-Americans in Technology"

Amarantus BioScience Holdings, Inc. Logo

SAN FRANCISCO, Jan. 15, 2014 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that both CSO Dr. John Commissiong and President & CEO Gerald Commissiong are among the selectees for the 14th Annual 50 Most Important African-Americans in Technology.

This is the third consecutive year that the Commissiongs have been honored with this distinction. Dr. John Commissiong will represent Amarantus at the event as selectees gather in Washington, D.C. January 15, 2014 for the 14th Annual Innovation and Equity Symposium.

"The fruits of our labor have begun to unfold and 2014 looks to be a year of significant progress for Amarantus," said John Commissiong, Chief Scientific Officer of Amarantus. "We are honored to be recognized for our efforts as part of this prestigious group."

About Black Money's 50 Most Important African-Americans in Technology

The listing of the 50 Most Important African-Americans in Technology began with an exhibition at The Tech Museum of Innovation in San Jose, California in 1998 to share the long-overlooked role of African-Americans in industrial innovation since the 19th century through the high-tech age. The 2011 selectees represent a fourth wave of innovation which has shaped the development of the U.S. economy. The 9th Annual Innovation and Equity Symposium featured the technical legacy of the Freedom Riders of the Cutting Edge -- Roy Clay Sr., a Silicon Valley Engineering Hall of Fame member; and the late Dr. Frank Greene Sr., Gerald A. Lawson and Ron Jones. Far too often overlooked, they are a key motivational force for increasing the participation of African-American students in mathematics and science courses. The 10th Annual Innovation & Equity Symposium led to the development of a biotechnology pilot high school in San Francisco. The 11th Annual Symposium was followed by testimony on Capitol Hill regarding African-American innovation, and the Catapult Innovation Showcase across the nation spurred manufacturing through innovation in black communities. Additionally, 'A Great Day in Gaming: From Queens to Silicon Valley: The Gerald A. Lawson Story' debuted in June at The Tech Museum of Innovation, just three months after his visit to the Game Developers Conference in March. More details on the 50 Most can be found at http://www.souloftechnology.com or http://www.blackmoney.com

About Amarantus

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfoling-related apoptosis. The Company has licensed Eltoprazine a phase 2b ready Parkinsons Levadopa induced diskynesia. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

CONTACT: Investor/Media Contacts Aimee Boutcher, Director of Investor Relations Amarantus Bioscience Holdings, Inc. 973 332-0121 ir@amarantus.com

Source:Amarantus BioScience Holdings, Inc.